Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.

Trial Details

NCT ID

NCT06376721

Phase

PHASE1 / PHASE2

Sponsor

Beijing Tongren Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Linperlisib
Camrelizumab
Pegaspargase
Dexamethasone

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria.
refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients
PET/CT or CT/MRI with at least one objectively evaluable lesion.
Expected to survive more than 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →